Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Schizophrenia

  Free Subscription


Articles published in Psychol Med

Retrieve available abstracts of 292 articles:
HTML format



Single Articles


    May 2024
  1. MAITRA R, Lemmers-Jansen ILJ, Vooren M, Vanes L, et al
    Understanding the mechanisms underlying cognitive control in psychosis.
    Psychol Med. 2024 May 23:1-10. doi: 10.1017/S0033291724001119.
    PubMed     Abstract available


  2. ANDERSON KK, Khan JA, Edwards J, Le B, et al
    Lost in translation? Deciphering the role of language differences in the excess risk of psychosis among migrant groups.
    Psychol Med. 2024 May 22:1-8. doi: 10.1017/S003329172400117.
    PubMed     Abstract available


  3. XUE R, Li X, Deng W, Liang C, et al
    Shared and distinct electroencephalogram microstate abnormalities across schizophrenia, bipolar disorder, and depression.
    Psychol Med. 2024 May 13:1-8. doi: 10.1017/S0033291724001132.
    PubMed     Abstract available


  4. SELTEN JP, Di Forti M, Quattrone D, Jones PB, et al
    The contribution of cannabis use to the increased psychosis risk among minority ethnic groups in Europe.
    Psychol Med. 2024 May 9:1-10. doi: 10.1017/S0033291724001004.
    PubMed     Abstract available


  5. DEMRO C, Lahud E, Burton PC, Purcell JR, et al
    Reward anticipation-related neural activation following cued reinforcement in adults with psychotic psychopathology and biological relatives.
    Psychol Med. 2024;54:1441-1451.
    PubMed     Abstract available


    April 2024
  6. UCOK A, Noyan H, Guloksuz S, Saka MC, et al
    The relationship between childhood trauma, psychotic symptoms, and cognitive schemas in patients with schizophrenia, their siblings, and healthy controls: results from the EU-GEI study.
    Psychol Med. 2024 Apr 12:1-12. doi: 10.1017/S0033291724000540.
    PubMed     Abstract available


  7. MOLINA JL, Joshi YB, Nungaray JA, Sprock J, et al
    Early auditory processing abnormalities alter individual learning trajectories and sensitivity to computerized cognitive training in schizophrenia.
    Psychol Med. 2024 Apr 8:1-8. doi: 10.1017/S0033291724000783.
    PubMed     Abstract available


  8. HJORTHOJ C, Sturup A, Karlsen M, Speyer H, et al
    Use of antipsychotic medication, benzodiazepines, and psychiatric hospitalization in cannabis-related versus cannabis-unrelated schizophrenia - a nationwide, register-based cohort study.
    Psychol Med. 2024 Apr 4:1-10. doi: 10.1017/S0033291724000758.
    PubMed     Abstract available


  9. JORGENSEN KN, Nerland S, Slapo NB, Norbom LB, et al
    Assessing regional intracortical myelination in schizophrenia spectrum and bipolar disorders using the optimized T1w/T2w-ratio.
    Psychol Med. 2024 Apr 2:1-11. doi: 10.1017/S0033291724000503.
    PubMed     Abstract available


  10. HANSEN HG, Gjode ICT, Starzer M, Ranning A, et al
    Clinical illness course and family-related outcomes among parents with a first episode of schizophrenia spectrum disorder: a 20-year follow-up of the OPUS trial.
    Psychol Med. 2024 Apr 2:1-10. doi: 10.1017/S0033291724000680.
    PubMed     Abstract available


  11. WANG J, Luo GY, Tian T, Zhao YQ, et al
    Shared genetic basis and causality between schizophrenia and inflammatory bowel disease: evidence from a comprehensive genetic analysis.
    Psychol Med. 2024 Apr 2:1-11. doi: 10.1017/S0033291724000771.
    PubMed     Abstract available


  12. MARCO-GARCIA S, Ariyo K, Owen GS, David AS, et al
    Decision making capacity for treatment in psychiatric inpatients: a systematic review and meta-analysis.
    Psychol Med. 2024;54:1074-1083.
    PubMed     Abstract available


  13. LAWRENCE JM, Breunig S, Foote IF, Tallis CB, et al
    Genomic SEM applied to explore etiological divergences in bipolar subtypes.
    Psychol Med. 2024;54:1152-1159.
    PubMed     Abstract available


    March 2024
  14. DENG L, Wei W, Qiao C, Yin Y, et al
    Dynamic aberrances of substantia nigra-relevant coactivation patterns in first-episode treatment-naive patients with schizophrenia.
    Psychol Med. 2024 Mar 25:1-11. doi: 10.1017/S0033291724000655.
    PubMed     Abstract available


  15. MELVILLE G, Hoffman M, Pollock A, Kurtz MM, et al
    Do metacognitive therapies for schizophrenia-spectrum disorders work? A meta-analytic investigation.
    Psychol Med. 2024 Mar 21:1-9. doi: 10.1017/S0033291724000564.
    PubMed     Abstract available


  16. CUESTA MJ, Garcia de Jalon E, Sanchez-Torres AM, Gil-Berrozpe GJ, et al
    Additive effects of a family history of schizophrenia spectrum disorders and an environmental risk score for the outcome of patients with non-affective first-episode psychosis.
    Psychol Med. 2024 Mar 20:1-9. doi: 10.1017/S0033291724000576.
    PubMed     Abstract available


  17. LUO C, Pi X, Zhang Q, Hu N, et al
    A subtype of schizophrenia patients with altered methylation level of genes related to immune cell activity.
    Psychol Med. 2024 Mar 20:1-9. doi: 10.1017/S0033291724000667.
    PubMed     Abstract available


  18. FORMICA MJC, Fuller-Tyszkiewicz M, Reininghaus U, Kempton M, et al
    Associations between disturbed sleep and attenuated psychotic experiences in people at clinical high risk for psychosis.
    Psychol Med. 2024 Mar 7:1-10. doi: 10.1017/S0033291724000400.
    PubMed     Abstract available


  19. LIU Y, Ren H, Zhang Y, Deng W, et al
    Temporal changes in brain morphology related to inflammation and schizophrenia: an omnigenic Mendelian randomization study.
    Psychol Med. 2024 Mar 6:1-9. doi: 10.1017/S003329172400014.
    PubMed     Abstract available


  20. BARNES-SCHEUFLER CV, Rosler L, Schaum M, Schiweck C, et al
    External cues improve visual working memory encoding in the presence of salient distractors in schizophrenia.
    Psychol Med. 2024 Mar 4:1-10. doi: 10.1017/S0033291724000059.
    PubMed     Abstract available


  21. ZHANG T, Cui H, Tang X, Xu L, et al
    Models of mild cognitive deficits in risk assessment in early psychosis.
    Psychol Med. 2024 Mar 4:1-12. doi: 10.1017/S0033291724000382.
    PubMed     Abstract available


  22. ROBINSON N, Ploner A, Leone M, Lichtenstein P, et al
    Environmental risk factors for schizophrenia and bipolar disorder from childhood to diagnosis: a Swedish nested case-control study.
    Psychol Med. 2024 Mar 1:1-10. doi: 10.1017/S0033291724000266.
    PubMed     Abstract available


    February 2024
  23. CORSI-ZUELLI F, Quattrone D, Ragazzi TCC, Loureiro CM, et al
    Transdiagnostic dimensions of symptoms and experiences associated with immune proteins in the continuity of psychosis.
    Psychol Med. 2024 Feb 28:1-13. doi: 10.1017/S0033291724000199.
    PubMed     Abstract available


  24. SIMONSEN C, Asbo G, Slade M, Wold KF, et al
    A good life with psychosis: rate of positive outcomes in first-episode psychosis at 10-year follow-up.
    Psychol Med. 2024 Feb 23:1-10. doi: 10.1017/S0033291724000205.
    PubMed     Abstract available


  25. LI X, Vaessen T, Lafit G, van Aubel E, et al
    Higher emotion regulation flexibility predicts more stable negative emotions and faster affective recovery in early psychosis: an experience sampling study.
    Psychol Med. 2024 Feb 12:1-10. doi: 10.1017/S0033291724000151.
    PubMed     Abstract available


  26. STARZER M, Hansen HG, Hjorthoj C, Albert N, et al
    20-year neurocognitive development following a schizophrenia spectrum disorder and associations with symptom severity and functional outcomes.
    Psychol Med. 2024 Feb 12:1-11. doi: 10.1017/S0033291724000096.
    PubMed     Abstract available


  27. GREEN MF, Wynn JK, Eisenberger NI, Horan WP, et al
    Social cognition and social motivation in schizophrenia and bipolar disorder: are impairments linked to the disorder or to being socially isolated?
    Psychol Med. 2024 Feb 5:1-9. doi: 10.1017/S0033291724000102.
    PubMed     Abstract available


  28. TORO VD, Antonucci LA, Quarto T, Passiatore R, et al
    The interaction between early life complications and a polygenic risk score for schizophrenia is associated with brain activity during emotion processing in healthy participants.
    Psychol Med. 2024 Feb 2:1-10. doi: 10.1017/S0033291724000011.
    PubMed     Abstract available


    January 2024
  29. D'ANDREA G, Quattrone D, Malone K, Tripoli G, et al
    Variation of subclinical psychosis across 16 sites in Europe and Brazil: findings from the multi-national EU-GEI study.
    Psychol Med. 2024 Jan 30:1-14. doi: 10.1017/S0033291723003781.
    PubMed     Abstract available


  30. ABPLANALP SJ, Braff DL, Light GA, Joshi YB, et al
    Clarifying directional dependence among measures of early auditory processing and cognition in schizophrenia: leveraging Gaussian graphical models and Bayesian networks.
    Psychol Med. 2024 Jan 30:1-10. doi: 10.1017/S0033291724000023.
    PubMed     Abstract available


  31. KORTE KJ, Jaguga F, Kim HH, Stroud RE, et al
    Psychometric Properties of the Mini International Neuropsychiatric Interview (MINI) Psychosis Module: A Sub-Saharan Africa Cross Country Comparison - CORRIGENDUM.
    Psychol Med. 2024 Jan 10:1. doi: 10.1017/S0033291723003835.
    PubMed    


  32. AKCAOGLU Z, Vaessen T, Velthorst E, Lafit G, et al
    The temporal association between social isolation, distress, and psychotic experiences in individuals at clinical high-risk for psychosis.
    Psychol Med. 2024 Jan 5:1-9. doi: 10.1017/S0033291723003598.
    PubMed     Abstract available


  33. BUCHWALD K, Narayanan A, Siegert RJ, Vignes M, et al
    Centrality statistics of symptom networks of schizophrenia: a systematic review.
    Psychol Med. 2024 Jan 4:1-13. doi: 10.1017/S003329172300363.
    PubMed     Abstract available


  34. DENG F, Bueber MA, Cao Y, Tang J, et al
    Assessing social cognition in patients with schizophrenia and healthy controls using the reading the mind in the eyes test (RMET): a systematic review and meta-regression.
    Psychol Med. 2024 Jan 4:1-27. doi: 10.1017/S0033291723003501.
    PubMed     Abstract available


  35. KENDLER KS, Keefe RSE, Ohlsson H, Sundquist J, et al
    Risk for psychiatric and substance use disorders as a function of transitions in Sweden's public educational system: a national study.
    Psychol Med. 2024;54:117-124.
    PubMed     Abstract available


    December 2023
  36. SALAZAR DE PABLO G, Aymerich C, Guinart D, Catalan A, et al
    What is the duration of untreated psychosis worldwide? - A meta-analysis of pooled mean and median time and regional trends and other correlates across 369 studies.
    Psychol Med. 2023 Dec 13:1-11. doi: 10.1017/S0033291723003458.
    PubMed     Abstract available


  37. SAARINEN A, Hietala J, Lyytikainen LP, Hamal Mishra B, et al
    Polygenic risk for schizophrenia predicting social trajectories in a general population sample.
    Psychol Med. 2023 Dec 4:1-9. doi: 10.1017/S003329172300346.
    PubMed     Abstract available


  38. POULOS J, Normand ST, Zelevinsky K, Newcomer JW, et al
    Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses.
    Psychol Med. 2023;53:7677-7684.
    PubMed     Abstract available


    November 2023
  39. COSTAS-CARRERA A, Verdolini N, Garcia-Rizo C, Mezquida G, et al
    Difficulties during delivery, brain ventricle enlargement and cognitive impairment in first episode psychosis.
    Psychol Med. 2023 Nov 28:1-11. doi: 10.1017/S0033291723003185.
    PubMed     Abstract available


  40. WANG B, Otten LJ, Schulze K, Afrah H, et al
    Is auditory processing measured by the N100 an endophenotype for psychosis? A family study and a meta-analysis.
    Psychol Med. 2023 Nov 24:1-14. doi: 10.1017/S0033291723003409.
    PubMed     Abstract available


  41. DI PRINZIO P, Morgan VA
    Early Adversity Scale for Schizophrenia (Short Form) (EAS-Sz (SF)).
    Psychol Med. 2023 Nov 23:1-3. doi: 10.1017/S0033291723003379.
    PubMed    


  42. PERALTA D, Janda L, Garcia de Jalon E, Moreno-Izco L, et al
    Long-term diagnostic stability, predictors of diagnostic change, and time until diagnostic change of first-episode psychosis: a 21-year follow-up study.
    Psychol Med. 2023 Nov 21:1-10. doi: 10.1017/S0033291723003173.
    PubMed     Abstract available


  43. MARTIN MC
    Correspondence to Freeman et al. (2023)'s virtual reality (VR) therapy for patients with psychosis: satisfaction and side effects.
    Psychol Med. 2023 Nov 6:1-2. doi: 10.1017/S0033291723003100.
    PubMed    


  44. LIVINGSTON NR, Fusar-Poli P, Modinos G
    Letter to the Editor on 'Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis'.
    Psychol Med. 2023 Nov 3:1-2. doi: 10.1017/S0033291723003203.
    PubMed    


  45. TROTTA G, Rodriguez V, Quattrone D, Spinazzola E, et al
    Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.
    Psychol Med. 2023;53:7375-7384.
    PubMed     Abstract available


  46. JAYASINGHE A, Wrobel A, Filia K, Byrne LK, et al
    Distress, burden, and wellbeing in siblings of people with mental illness: a mixed studies systematic review and meta-analysis.
    Psychol Med. 2023;53:6945-6964.
    PubMed     Abstract available


    October 2023
  47. VARESE F, Sellwood W, Pulford D, Awenat Y, et al
    Trauma-focused therapy in early psychosis: results of a feasibility randomized controlled trial of EMDR for psychosis (EMDRp) in early intervention settings.
    Psychol Med. 2023 Oct 26:1-12. doi: 10.1017/S0033291723002532.
    PubMed     Abstract available


  48. KAPLER S, Adery L, Hoftman GD, Amir CM, et al
    Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool.
    Psychol Med. 2023 Oct 26:1-11. doi: 10.1017/S0033291723002994.
    PubMed     Abstract available


  49. PETKARI E, Nikolaou E, Oberleiter S, Priebe S, et al
    Which psychological interventions improve quality of life in patients with schizophrenia-spectrum disorders? A meta-analysis of randomized controlled trials.
    Psychol Med. 2023 Oct 20:1-24. doi: 10.1017/S0033291723003070.
    PubMed     Abstract available


  50. DAVIES C, Bossong MG, Martins D, Wilson R, et al
    Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
    Psychol Med. 2023 Oct 17:1-11. doi: 10.1017/S0033291723002775.
    PubMed     Abstract available


  51. MULLIGAN LD, Varese F, Harris K, Haddock G, et al
    Alcohol use and suicide-related outcomes in people with a diagnosis of schizophrenia: a comprehensive systematic review and meta-analysis.
    Psychol Med. 2023 Oct 11:1-12. doi: 10.1017/S0033291723002738.
    PubMed     Abstract available


  52. VENTURA J, Subotnik KL, Han S, Hellemann GS, et al
    The relationship between sex and functional outcome in first-episode schizophrenia: the role of premorbid adjustment and insight.
    Psychol Med. 2023;53:6878-6887.
    PubMed     Abstract available


    September 2023
  53. YAU KC, Revill G, Blackman G, Shaikh M, et al
    Pediatric traumatic brain injury as a risk factor for psychosis and psychotic symptoms: a systematic review and meta-analysis.
    Psychol Med. 2023 Sep 29:1-9. doi: 10.1017/S0033291723002878.
    PubMed     Abstract available


  54. HOTTE-MEUNIER A, Penney D, Mendelson D, Thibaudeau E, et al
    Effects of metacognitive training (MCT) on social cognition for schizophrenia spectrum and related psychotic disorders: a systematic review and meta-analysis.
    Psychol Med. 2023 Sep 29:1-7. doi: 10.1017/S0033291723002611.
    PubMed     Abstract available


  55. GOH KK, Kanahara N, Chiu YH, Lu ML, et al
    The impact of childhood trauma exposure on social functioning in schizophrenia: the moderated mediation role of oxytocin and oxytocin receptor gene polymorphisms.
    Psychol Med. 2023 Sep 18:1-13. doi: 10.1017/S003329172300274.
    PubMed     Abstract available


  56. BIAGGI A, Hazelgrove K, Waites F, Bind RH, et al
    Mother-infant interaction and infant development in women at risk of postpartum psychosis with and without a postpartum relapse.
    Psychol Med. 2023 Sep 14:1-12. doi: 10.1017/S0033291723002568.
    PubMed     Abstract available


  57. DONALDSON KR, Jonas K, Foti D, Larsen EM, et al
    Mismatch negativity and clinical trajectories in psychotic disorders: Five-year stability and predictive utility.
    Psychol Med. 2023;53:5818-5828.
    PubMed     Abstract available


  58. HAVERS L, von Stumm S, Cardno AG, Freeman D, et al
    Psychotic experiences and negative symptoms from adolescence to emerging adulthood: developmental trajectories and associations with polygenic scores and childhood characteristics.
    Psychol Med. 2023;53:5685-5697.
    PubMed     Abstract available


    August 2023
  59. WORTHINGTON MA, Collins MA, Addington J, Bearden CE, et al
    Improving prediction of psychosis in youth at clinical high-risk: pre-baseline symptom duration and cortical thinning as moderators of the NAPLS2 risk calculator.
    Psychol Med. 2023 Aug 29:1-9. doi: 10.1017/S0033291723002301.
    PubMed     Abstract available


  60. STAINTON A, Wood SJ, Allott K
    Reply to 'Tailoring Cognitive Interventions to Individuals' Cognitive Profiles: Commentary on "Prevalence of Cognitive Impairments and Strengths in the Early Course of Psychosis and Depression" by Stainton et al.'.
    Psychol Med. 2023 Aug 24:1-2. doi: 10.1017/S0033291723002337.
    PubMed    


  61. BINBAY T, Mollaahmetoglu OM, Kirli U, Arik D, et al
    Treated incidence of first episode psychosis in Sinop, Turkey: results of a 4-year admission-based study - SINOPsy.
    Psychol Med. 2023 Aug 23:1-11. doi: 10.1017/S0033291723002192.
    PubMed     Abstract available


  62. RABALLO A, Poletti M, Preti A
    Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis.
    Psychol Med. 2023 Aug 23:1-7. doi: 10.1017/S0033291723002180.
    PubMed     Abstract available


  63. VAN ASSCHE L, Takamiya A, Van den Stock J, Van de Ven L, et al
    A voxel- and source-based morphometry analysis of grey matter volume differences in very-late-onset schizophrenia-like psychosis.
    Psychol Med. 2023 Aug 14:1-9. doi: 10.1017/S0033291723002258.
    PubMed     Abstract available


  64. TERMORSHUIZEN F, de Vries ALC, Wiepjes CM, Selten JP, et al
    The risk of psychosis for transgender individuals: a Dutch national cohort study.
    Psychol Med. 2023 Aug 4:1-10. doi: 10.1017/S0033291723002088.
    PubMed     Abstract available


    July 2023
  65. DOUGLAS KM, Thwaites B, Frawley E, Hammar A, et al
    Tailoring cognitive interventions to individuals' cognitive profiles: commentary on 'Prevalence of cognitive impairments and strengths in the early course of psychosis and depression' by Stainton et al.
    Psychol Med. 2023 Jul 31:1-3. doi: 10.1017/S0033291723002076.
    PubMed    


  66. VITA A, Barlati S, Deste G, Nibbio G, et al
    Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community.
    Psychol Med. 2023 Jul 31:1-10. doi: 10.1017/S0033291723002106.
    PubMed     Abstract available


  67. ALVAREZ R, Velthorst E, Pinkham A, Ludwig KA, et al
    Reading the mind in the eyes and cognitive ability in schizophrenia- and autism spectrum disorders.
    Psychol Med. 2023 Jul 31:1-10. doi: 10.1017/S0033291723002052.
    PubMed     Abstract available


  68. JOO SW, Jo YT, Kim Y, Lee WH, et al
    Structural variability of the cerebral cortex in schizophrenia and its association with clinical symptoms.
    Psychol Med. 2023 Jul 24:1-10. doi: 10.1017/S0033291723001988.
    PubMed     Abstract available


  69. ENTHOVEN AD, Gangadin SS, de Haan L, Veling W, et al
    The association of childhood trauma with depressive and negative symptoms in recent onset psychosis: a sex-specific analysis.
    Psychol Med. 2023 Jul 12:1-10. doi: 10.1017/S0033291723001824.
    PubMed     Abstract available


  70. STAINTON A, Chisholm K, Griffiths SL, Kambeitz-Ilankovic L, et al
    Prevalence of cognitive impairments and strengths in the early course of psychosis and depression.
    Psychol Med. 2023 Jul 6:1-13. doi: 10.1017/S0033291723001770.
    PubMed     Abstract available


  71. ZARUBIN VC, Damme KSF, Vargas T, Osborne KJ, et al
    Neurodevelopmental vulnerability to psychosis: developmentally-based methods enable detection of early life inhibitory control deficits that predict psychotic-like experiences at the transition to adolescence.
    Psychol Med. 2023 Jul 3:1-10. doi: 10.1017/S003329172300171.
    PubMed     Abstract available


  72. SEGURA AG, Mezquida G, Martinez-Pinteno A, Gasso P, et al
    Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode.
    Psychol Med. 2023;53:4634-4647.
    PubMed     Abstract available


  73. MA R, Romano E, Ashworth M, Yadegarfar ME, et al
    Multimorbidity clusters among people with serious mental illness: a representative primary and secondary data linkage cohort study.
    Psychol Med. 2023;53:4333-4344.
    PubMed     Abstract available


  74. SHUNKAI L, Chen P, Zhong S, Chen G, et al
    Alterations of insular dynamic functional connectivity and psychological characteristics in unmedicated bipolar depression patients with a recent suicide attempt.
    Psychol Med. 2023;53:3837-3848.
    PubMed     Abstract available


    June 2023
  75. RICHARDS-BELLE A, Poole N, Osborn DPJ, Bell V, et al
    Longitudinal associations between stroke and psychosis: a population-based study.
    Psychol Med. 2023 Jun 5:1-9. doi: 10.1017/S0033291723001575.
    PubMed     Abstract available


  76. VARGAS TG, Mittal VA
    Brain morphometry points to emerging patterns of psychosis, depression, and anxiety vulnerability over a 2-year period in childhood.
    Psychol Med. 2023;53:3322-3334.
    PubMed     Abstract available


  77. BURTON BK, Andersen KK, Greve AN, Hemager N, et al
    Sex differences across developmental domains among children with a familial risk of severe mental disorders.
    Psychol Med. 2023;53:3628-3643.
    PubMed     Abstract available


    May 2023
  78. LUTHER L, Raugh IM, Collins DE, Berglund A, et al
    Environmental context predicts state fluctuations in negative symptoms in youth at clinical high risk for psychosis.
    Psychol Med. 2023 May 29:1-10. doi: 10.1017/S0033291723001393.
    PubMed     Abstract available


  79. VAN DER TUIN S, Booij SH, Oldehinkel AJ, van den Berg D, et al
    The dynamic relationship between sleep and psychotic experiences across the early stages of the psychosis continuum.
    Psychol Med. 2023 May 23:1-9. doi: 10.1017/S0033291723001459.
    PubMed     Abstract available


  80. RAMAIN J, Abrahamyan Empson L, Alameda L, Solida A, et al
    The co-occurrence of manic and depressive dimensions in early psychosis: a latent transition analysis.
    Psychol Med. 2023 May 19:1-8. doi: 10.1017/S003329172300137.
    PubMed     Abstract available


  81. BRAND BA, Haveman YRA, de Beer F, de Boer JN, et al
    Antipsychotic medication for women with schizophrenia spectrum disorders - CORRIGENDUM.
    Psychol Med. 2023 May 10:1. doi: 10.1017/S0033291723001344.
    PubMed    


  82. KONSTANTIN GE, Nordgaard J, Henriksen MG
    Methodological issues in social cognition research in autism spectrum disorder and schizophrenia spectrum disorder: a systematic review.
    Psychol Med. 2023 May 10:1-12. doi: 10.1017/S0033291723001095.
    PubMed     Abstract available


  83. PETKARI E, Martin-Maria N, Sanchez-Gutierrez T, Fernandez-Castilla B, et al
    A meta-analysis of cognitive interventions for patients with recent onset psychosis: are they effective for improving functioning?
    Psychol Med. 2023 May 10:1-16. doi: 10.1017/S0033291723001198.
    PubMed     Abstract available


  84. HJORTHOJ C, Compton W, Starzer M, Nordholm D, et al
    Association between cannabis use disorder and schizophrenia stronger in young males than in females.
    Psychol Med. 2023 May 4:1-7. doi: 10.1017/S0033291723000880.
    PubMed     Abstract available


  85. SPINAZZOLA E, Quattrone D, Rodriguez V, Trotta G, et al
    The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.
    Psychol Med. 2023 May 2:1-10. doi: 10.1017/S0033291723001071.
    PubMed     Abstract available


  86. PILLINGER T, McCutcheon RA, Howes OD
    Variability of glucose, insulin, and lipid disturbances in first-episode psychosis: a meta-analysis.
    Psychol Med. 2023;53:3150-3156.
    PubMed     Abstract available


  87. PARKIN K, Chen S, Biria M, Plaistow J, et al
    Clozapine-related obsessive-compulsive symptoms and their impact on wellbeing: a naturalistic longitudinal study.
    Psychol Med. 2023;53:2936-2945.
    PubMed     Abstract available


  88. ADAMS RL, Baird A, Smith J, Williams N, et al
    Psychopathology in adults with copy number variants.
    Psychol Med. 2023;53:3142-3149.
    PubMed     Abstract available


    April 2023
  89. SANCHEZ-GUTIERREZ T, Rodriguez-Toscano E, Roldan L, Ferraro L, et al
    Tobacco use in first-episode psychosis, a multinational EU-GEI study.
    Psychol Med. 2023 Apr 26:1-12. doi: 10.1017/S0033291723000806.
    PubMed     Abstract available


  90. BUTTER S, Shevlin M, McBride O, Bentall RP, et al
    Functioning, symptom expression and risk along the psychosis continuum.
    Psychol Med. 2023 Apr 24:1-11. doi: 10.1017/S0033291723001046.
    PubMed     Abstract available


  91. ZHANG C, Li X, Zhao L, Guo W, et al
    Brain transcriptome-wide association study implicates novel risk genes underlying schizophrenia risk.
    Psychol Med. 2023 Apr 24:1-11. doi: 10.1017/S0033291723000417.
    PubMed     Abstract available


  92. MODASI J, Khachadourian V, O'Hora K, Kushan L, et al
    Associations between acute and chronic lifetime stressors and psychosis-risk symptoms in individuals with 22q11.2 copy number variants.
    Psychol Med. 2023 Apr 20:1-10. doi: 10.1017/S0033291723000740.
    PubMed     Abstract available


  93. JONKER I, Doorduin J, Knegtering H, Van't Hag E, et al
    Antiviral treatment in schizophrenia: a randomized pilot PET study on the effects of valaciclovir on neuroinflammation.
    Psychol Med. 2023 Apr 5:1-9. doi: 10.1017/S0033291723000430.
    PubMed     Abstract available


  94. OTTESEN A, T V Hegelstad W, Joa I, Opjordsmoen SE, et al
    Childhood trauma, antipsychotic medication, and symptom remission in first-episode psychosis.
    Psychol Med. 2023;53:2399-2408.
    PubMed     Abstract available


  95. AAS M, Alameda L, Di Forti M, Quattrone D, et al
    Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study.
    Psychol Med. 2023;53:1970-1978.
    PubMed     Abstract available


  96. ELKRIEF L, Lin B, Marchi M, Afzali MH, et al
    Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene x environment moderation and mediation.
    Psychol Med. 2023;53:1759-1769.
    PubMed     Abstract available


  97. AYESA-ARRIOLA R, de la Foz VO, Murillo-Garcia N, Vazquez-Bourgon J, et al
    Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort.
    Psychol Med. 2023;53:1891-1905.
    PubMed     Abstract available


  98. MILEY K, Meyer-Kalos P, Ma S, Bond DJ, et al
    Causal pathways to social and occupational functioning in the first episode of schizophrenia: uncovering unmet treatment needs.
    Psychol Med. 2023;53:2041-2049.
    PubMed     Abstract available


  99. BETZ LT, Penzel N, Rosen M, Bhui K, et al
    Disentangling heterogeneity of psychosis expression in the general population: sex-specific moderation effects of environmental risk factors on symptom networks.
    Psychol Med. 2023;53:1860-1869.
    PubMed     Abstract available


  100. KRANTZ MF, Hjorthoj C, Brandt JM, Prosch AK, et al
    Home environment of 11-year-old children born to parents with schizophrenia or bipolar disorder - a controlled, 4-year follow-up study: The Danish High Risk and Resilience Study - VIA 11.
    Psychol Med. 2023;53:2563-2573.
    PubMed     Abstract available


  101. LI S, Chan SY, Higgins A, Hall MH, et al
    Sensory gating, neurocognition, social cognition and real-life functioning: a 2-year follow-up of early psychosis.
    Psychol Med. 2023;53:2540-2552.
    PubMed     Abstract available


  102. PERALTA V, Cuesta MJ
    Schneider's first-rank symptoms have neither diagnostic value for schizophrenia nor higher clinical validity than other delusions and hallucinations in psychotic disorders.
    Psychol Med. 2023;53:2708-2711.
    PubMed     Abstract available


    March 2023
  103. WANG X, Zhang Y, Huang J, Wang Y, et al
    Revisiting reward impairments in schizophrenia spectrum disorders: a systematic review and meta-analysis for neuroimaging findings.
    Psychol Med. 2023 Mar 30:1-14. doi: 10.1017/S0033291723000703.
    PubMed     Abstract available


  104. GUR RE, McDonald-McGinn DM, Moore TM, Gallagher RS, et al
    Psychosis spectrum features, neurocognition and functioning in a longitudinal study of youth with 22q11.2 deletion syndrome.
    Psychol Med. 2023 Mar 29:1-10. doi: 10.1017/S0033291723000259.
    PubMed     Abstract available


  105. FUENTES-CLARAMONTE P, Garcia-Leon MA, Salgado-Pineda P, Ramiro N, et al
    Do the negative symptoms of schizophrenia reflect reduced responsiveness to reward? Examination using a reward prediction error (RPE) task.
    Psychol Med. 2023 Mar 29:1-10. doi: 10.1017/S0033291723000521.
    PubMed     Abstract available


  106. KORTE KJ, Jaguga F, Kim HH, Stroud RE, et al
    Psychometric properties of the mini international neuropsychiatric interview (MINI) psychosis module: a Sub-Saharan Africa cross country comparison.
    Psychol Med. 2023 Mar 10:1-11. doi: 10.1017/S0033291723000296.
    PubMed     Abstract available


  107. LIU CC, Hsieh MH, Chien YL, Liu CM, et al
    Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort.
    Psychol Med. 2023 Mar 10:1-9. doi: 10.1017/S0033291723000429.
    PubMed     Abstract available


  108. CUESTA MJ, Papiol S, Ibanez B, Garcia de Jalon E, et al
    Effect of polygenic risk score, family load of schizophrenia and exposome risk score, and their interactions, on the long-term outcome of first-episode psychosis.
    Psychol Med. 2023 Mar 6:1-10. doi: 10.1017/S0033291723000351.
    PubMed     Abstract available


  109. AL-SOUFI L, Costas J
    Genetic susceptibility for schizophrenia after adjustment by genetic susceptibility for smoking: implications in identification of risk genes and genetic correlation with related traits.
    Psychol Med. 2023 Mar 6:1-11. doi: 10.1017/S0033291723000326.
    PubMed     Abstract available


  110. TANGMOSE K, Rostrup E, Bojesen KB, Sigvard A, et al
    Reward disturbances in antipsychotic-naive patients with first-episode psychosis and their association to glutamate levels.
    Psychol Med. 2023;53:1629-1638.
    PubMed     Abstract available


  111. ANDREOU D, Steen NE, Jorgensen KN, Smelror RE, et al
    Lower circulating neuron-specific enolase concentrations in adults and adolescents with severe mental illness.
    Psychol Med. 2023;53:1479-1488.
    PubMed     Abstract available


  112. SHEN H, Zhang L, Li Y, Zheng D, et al
    Mindfulness-based intervention improves residual negative symptoms and cognitive impairment in schizophrenia: a randomized controlled follow-up study.
    Psychol Med. 2023;53:1390-1399.
    PubMed     Abstract available


    February 2023
  113. PELOSI AJ, Arulnathan V
    Neglecting the care of people with schizophrenia: here we go again.
    Psychol Med. 2023 Feb 20:1-6. doi: 10.1017/S0033291723000247.
    PubMed     Abstract available


  114. BELKACEM A, Lonergan M, Feizi S, Brunet A, et al
    Letter to the editor: the longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Psychol Med. 2023 Feb 15:1-2. doi: 10.1017/S0033291723000065.
    PubMed    


  115. BOJESEN KB, Glenthoj BY, Sigvard AK, Tangmose K, et al
    Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naive patients with psychosis.
    Psychol Med. 2023 Feb 9:1-11. doi: 10.1017/S0033291723000144.
    PubMed     Abstract available


  116. CULBRETH AJ, Schwartz EK, Frank MJ, Brown EC, et al
    A computational neuroimaging study of reinforcement learning and goal-directed exploration in schizophrenia spectrum disorders.
    Psychol Med. 2023 Feb 8:1-11. doi: 10.1017/S0033291722003993.
    PubMed     Abstract available


  117. BRANDT JM, Gregersen M, Sondergaard A, Krantz MF, et al
    Associations between exposure to early childhood adversities and middle childhood psychotic experiences in children at familial high risk of schizophrenia, bipolar disorder, and population-based controls: The Danish high risk and resilience study - VI
    Psychol Med. 2023 Feb 2:1-11. doi: 10.1017/S0033291722004020.
    PubMed     Abstract available


  118. BARTOLOMEO LA, Raugh IM, Strauss GP
    The positivity offset theory of anhedonia in schizophrenia: evidence for a deficit in daily life using digital phenotyping.
    Psychol Med. 2023 Feb 1:1-9. doi: 10.1017/S0033291722003774.
    PubMed     Abstract available


  119. PIERRE JM, Zito MF, Yang YS, Marder SR, et al
    Antipsychotic discontinuation and recovery: chicken or egg?
    Psychol Med. 2023;53:1134-1135.
    PubMed    


  120. LEHTI V, Taipale H, Gissler M, Tanskanen A, et al
    Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study.
    Psychol Med. 2023;53:833-843.
    PubMed     Abstract available


    January 2023
  121. SELTEN JP, Ormel J
    Low status, humiliation, dopamine and risk of schizophrenia.
    Psychol Med. 2023 Jan 25:1-5. doi: 10.1017/S0033291722003816.
    PubMed     Abstract available


  122. CHIEN WT, Bressington D, Yip A, Karatzias T, et al
    An international multi-site, randomized controlled trial of a mindfulness-based psycho-education group program for people with schizophrenia - CORRIGENDUM.
    Psychol Med. 2023 Jan 20:1. doi: 10.1017/S0033291723000041.
    PubMed    


  123. CHAVEZ-BALDINI U, Nieman DH, Keestra A, Lok A, et al
    The relationship between cognitive functioning and psychopathology in patients with psychiatric disorders: a transdiagnostic network analysis.
    Psychol Med. 2023;53:476-485.
    PubMed     Abstract available


  124. FU XL, Qian Y, Jin XH, Yu HR, et al
    Suicide rates among people with serious mental illness: a systematic review and meta-analysis.
    Psychol Med. 2023;53:351-361.
    PubMed     Abstract available


  125. SELTEN JP
    The social defeat hypothesis of schizophrenia is more topical than ever. Reply to Schalbroeck.
    Psychol Med. 2023;53:290-291.
    PubMed    


  126. SCHALBROECK R
    The social defeat hypothesis of schizophrenia: a parsimonious explanation for multiple psychosis risk factors?
    Psychol Med. 2023;53:286-287.
    PubMed    


    December 2022
  127. DE HAAN L, van Tricht M, van Dijk F, Arango C, et al
    Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders.
    Psychol Med. 2022 Dec 15:1-6. doi: 10.1017/S0033291722003142.
    PubMed     Abstract available


  128. MORALES-PILLADO C, Fernandez-Castilla B, Sanchez-Gutierrez T, Gonzalez-Fraile E, et al
    Efficacy of technology-based interventions in psychosis: a systematic review and network meta-analysis.
    Psychol Med. 2022 Dec 6:1-12. doi: 10.1017/S0033291722003610.
    PubMed     Abstract available


    November 2022
  129. SMUCNY J, Lesh TA, Niendam TA, Ragland JD, et al
    Evidence for functional improvement in reward anticipation in recent onset schizophrenia after one year of coordinated specialty care.
    Psychol Med. 2022 Nov 24:1-8. doi: 10.1017/S0033291722003592.
    PubMed     Abstract available


  130. KUO SS, Ventura J, Forsyth JK, Subotnik KL, et al
    Developmental trajectories of premorbid functioning predict cognitive remediation treatment response in first-episode schizophrenia.
    Psychol Med. 2022 Nov 9:1-10. doi: 10.1017/S0033291722003312.
    PubMed     Abstract available


  131. VALT C, Quarto T, Tavella A, Romanelli F, et al
    Reduced magnetic mismatch negativity: a shared deficit in psychosis and related risk.
    Psychol Med. 2022 Nov 2:1-9. doi: 10.1017/S003329172200321.
    PubMed     Abstract available


    October 2022
  132. D'ANDREA G, Lal J, Tosato S, Gayer-Anderson C, et al
    Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study.
    Psychol Med. 2022 Oct 28:1-11. doi: 10.1017/S003329172200335.
    PubMed     Abstract available


  133. GUPTA T, Osborne KJ, Nadig A, Haase CM, et al
    Alterations in facial expressions in individuals at risk for psychosis: a facial electromyography approach using emotionally evocative film clips.
    Psychol Med. 2022 Oct 26:1-10. doi: 10.1017/S0033291722003087.
    PubMed     Abstract available


  134. ANTONUCCI LA, Pergola G, Rampino A, Rocca P, et al
    Clinical and psychological factors associated with resilience in patients with schizophrenia: data from the Italian network for research on psychoses using machine learning.
    Psychol Med. 2022 Oct 11:1-12. doi: 10.1017/S003329172200294.
    PubMed     Abstract available


  135. FRYER SL, Ferri JM, Roach BJ, Loewy RL, et al
    Thalamic dysconnectivity in the psychosis risk syndrome and early illness schizophrenia.
    Psychol Med. 2022;52:2767-2775.
    PubMed     Abstract available


  136. KLIPPEL A, Schick A, Myin-Germeys I, Rauschenberg C, et al
    Modelling the temporal interplay between stress and affective disturbances in pathways to psychosis: an experience sampling study.
    Psychol Med. 2022;52:2776-2785.
    PubMed     Abstract available


  137. HUANG LY, Jackson BS, Rodrigue AL, Tamminga CA, et al
    Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2).
    Psychol Med. 2022;52:2692-2701.
    PubMed     Abstract available


  138. HARROW M, Jobe TH, Tong L
    Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders.
    Psychol Med. 2022;52:2681-2691.
    PubMed     Abstract available


  139. LIU N, Lencer R, Yang Z, Zhang W, et al
    Altered functional synchrony between gray and white matter as a novel indicator of brain system dysconnectivity in schizophrenia.
    Psychol Med. 2022;52:2540-2548.
    PubMed     Abstract available


  140. MEYER N, Joyce DW, Karr C, de Vos M, et al
    The temporal dynamics of sleep disturbance and psychopathology in psychosis: a digital sampling study.
    Psychol Med. 2022;52:2741-2750.
    PubMed     Abstract available


  141. KOIKE S, Sakakibara E, Satomura Y, Sakurada H, et al
    Shared functional impairment in the prefrontal cortex affects symptom severity across psychiatric disorders.
    Psychol Med. 2022;52:2661-2670.
    PubMed     Abstract available


  142. BERGE D, Lesh TA, Smucny J, Carter CS, et al
    Improvement in prefrontal thalamic connectivity during the early course of the illness in recent-onset psychosis: a 12-month longitudinal follow-up resting-state fMRI study.
    Psychol Med. 2022;52:2713-2721.
    PubMed     Abstract available


  143. LEE TY, Hwang WJ, Kim NS, Park I, et al
    Prediction of psychosis: model development and internal validation of a personalized risk calculator.
    Psychol Med. 2022;52:2632-2640.
    PubMed     Abstract available


  144. CHEN KC, Yang YK, Howes OD, Lee IH, et al
    Striatal dopamine D(2/3) receptors in medication-naive schizophrenia: an [(123)I] IBZM SPECT study.
    Psychol Med. 2022;52:3251-3259.
    PubMed     Abstract available


  145. PIAO YH, Yun JY, Nguyen TB, Kim WS, et al
    Longitudinal symptom network structure in first-episode psychosis: a possible marker for remission.
    Psychol Med. 2022;52:3193-3201.
    PubMed     Abstract available


  146. TARRICONE I, D'Andrea G, Jongsma HE, Tosato S, et al
    Migration history and risk of psychosis: results from the multinational EU-GEI study.
    Psychol Med. 2022;52:2972-2984.
    PubMed     Abstract available


  147. RINGIN E, Cropley V, Zalesky A, Bruggemann J, et al
    The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders.
    Psychol Med. 2022;52:3097-3115.
    PubMed     Abstract available


  148. FIKSINSKI AM, Heung T, Corral M, Breetvelt EJ, et al
    Within-family influences on dimensional neurobehavioral traits in a high-risk genetic model.
    Psychol Med. 2022;52:3184-3192.
    PubMed     Abstract available


  149. MOORE TM, Calkins ME, Rosen AFG, Butler ER, et al
    Development of a probability calculator for psychosis risk in children, adolescents, and young adults.
    Psychol Med. 2022;52:3159-3167.
    PubMed     Abstract available


    September 2022
  150. VOUGA RIBEIRO N, Tavares V, Bramon E, Toulopoulou T, et al
    Effects of psychosis-associated genetic markers on brain volumetry: a systematic review of replicated findings and an independent validation.
    Psychol Med. 2022 Sep 28:1-16. doi: 10.1017/S0033291722002896.
    PubMed     Abstract available


  151. WANG YZ, Weng X, Zhang TM, Li M, et al
    Effectiveness of enhancing contact model on reducing family caregiving burden and improving psychological wellbeing among caregivers of persons with schizophrenia in rural China.
    Psychol Med. 2022 Sep 26:1-11. doi: 10.1017/S0033291722002987.
    PubMed     Abstract available


  152. FAN F, Tan S, Liu S, Chen S, et al
    Subcortical structures associated with childhood trauma and perceived stress in schizophrenia.
    Psychol Med. 2022 Sep 26:1-9. doi: 10.1017/S0033291722002860.
    PubMed     Abstract available


  153. LIN JY, Yeh LL, Pan YJ
    Exposure to psychotropic medications and mortality in schizophrenia: a 5-year national cohort study.
    Psychol Med. 2022 Sep 22:1-10. doi: 10.1017/S0033291722002732.
    PubMed     Abstract available


  154. RADHAKRISHNAN R, Pries LK, Erzin G, Ten Have M, et al
    Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis.
    Psychol Med. 2022 Sep 12:1-7. doi: 10.1017/S0033291722002756.
    PubMed     Abstract available


  155. MALLET J, Godin O, Dansou Y, Mazer N, et al
    Current (but not ex) cigarette smoking is associated with worse cognitive performances in schizophrenia: results from the FACE-SZ cohort.
    Psychol Med. 2022 Sep 8:1-12. doi: 10.1017/S0033291722002574.
    PubMed     Abstract available


  156. RAMSAY IS, Mueller B, Ma Y, Shen C, et al
    Thalamocortical connectivity and its relationship with symptoms and cognition across the psychosis continuum.
    Psychol Med. 2022 Sep 1:1-10. doi: 10.1017/S0033291722002793.
    PubMed     Abstract available


  157. SARPAL DK, Tarcijonas G, Calabro FJ, Foran W, et al
    Context-specific abnormalities of the central executive network in first-episode psychosis: relationship with cognition.
    Psychol Med. 2022;52:2299-2308.
    PubMed     Abstract available


  158. FAN F, Tan S, Huang J, Chen S, et al
    Functional disconnection between subsystems of the default mode network in schizophrenia.
    Psychol Med. 2022;52:2270-2280.
    PubMed     Abstract available


  159. GUIMOND S, Ling G, Drodge J, Matheson H, et al
    Functional connectivity associated with improvement in emotion management after cognitive enhancement therapy in early-course schizophrenia.
    Psychol Med. 2022;52:2245-2254.
    PubMed     Abstract available


    August 2022
  160. SELVAGGI P, Jauhar S, Kotoula V, Pepper F, et al
    Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response.
    Psychol Med. 2022 Aug 25:1-11. doi: 10.1017/S0033291722002288.
    PubMed     Abstract available


  161. ROGNLI EB, Taipale H, Hjorthoj C, Mittendorfer-Rutz E, et al
    Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016.
    Psychol Med. 2022 Aug 19:1-10. doi: 10.1017/S003329172200229.
    PubMed     Abstract available


  162. AMORETTI S, Rabelo-da-Ponte FD, Garriga M, Forte MF, et al
    Obstetric complications and cognition in schizophrenia: a systematic review and meta-analysis.
    Psychol Med. 2022 Aug 18:1-11. doi: 10.1017/S0033291722002409.
    PubMed     Abstract available


  163. PRASANNAKUMAR A, Kumar V, Rao NP
    Trust and psychosis: a systematic review and meta-analysis.
    Psychol Med. 2022 Aug 17:1-9. doi: 10.1017/S0033291722002562.
    PubMed     Abstract available


  164. OHI K, Nishizawa D, Sugiyama S, Takai K, et al
    Cognitive performances across individuals at high genetic risk for schizophrenia, high genetic risk for bipolar disorder, and low genetic risks: a combined polygenic risk score approach.
    Psychol Med. 2022 Aug 16:1-10. doi: 10.1017/S0033291722001271.
    PubMed     Abstract available


  165. NUECHTERLEIN KH, McEwen SC, Ventura J, Subotnik KL, et al
    Aerobic exercise enhances cognitive training effects in first-episode schizophrenia: randomized clinical trial demonstrates cognitive and functional gains.
    Psychol Med. 2022 Aug 8:1-11. doi: 10.1017/S0033291722001696.
    PubMed     Abstract available


  166. GURVICH C, Thomas N, Hudaib AR, Van Rheenen TE, et al
    The relationship between cognitive clusters and telomere length in bipolar-schizophrenia spectrum disorders.
    Psychol Med. 2022 Aug 3:1-8. doi: 10.1017/S0033291722002148.
    PubMed     Abstract available


    July 2022
  167. HEDGES EP, See C, Si S, McGuire P, et al
    Meta-analysis of longitudinal neurocognitive performance in people at clinical high-risk for psychosis.
    Psychol Med. 2022 Jul 13:1-8. doi: 10.1017/S0033291722001830.
    PubMed     Abstract available


  168. STURUP AE, Nordentoft M, Jimenez-Solem E, Osler M, et al
    Discontinuation of antipsychotics in individuals with first-episode schizophrenia and its association to functional outcomes, hospitalization and death: a register-based nationwide follow-up study.
    Psychol Med. 2022 Jul 12:1-9. doi: 10.1017/S0033291722002021.
    PubMed     Abstract available


  169. DI PRINZIO P, Bjork J, Valuri G, Ambrosi T, et al
    Development and initial validation of a multivariable predictive Early Adversity Scale for Schizophrenia (EAS-Sz) using register data to quantify environmental risk for adult schizophrenia diagnosis after childhood exposure to adversity.
    Psychol Med. 2022 Jul 12:1-11. doi: 10.1017/S0033291722001945.
    PubMed     Abstract available


  170. SEITZ-HOLLAND J, Nagele FL, Kubicki M, Pasternak O, et al
    Shared and distinct white matter abnormalities in adolescent-onset schizophrenia and adolescent-onset psychotic bipolar disorder.
    Psychol Med. 2022 Jul 7:1-13. doi: 10.1017/S003329172200160.
    PubMed     Abstract available


  171. CAI XL, Pu CC, Zhou SZ, Wang Y, et al
    Anterior cingulate glutamate levels associate with functional activation and connectivity during sensory integration in schizophrenia: a multimodal (1)H-MRS and fMRI study.
    Psychol Med. 2022 Jul 6:1-11. doi: 10.1017/S0033291722001817.
    PubMed     Abstract available


  172. VENTURA AMB, Hayes RD, Fonseca de Freitas D
    Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review.
    Psychol Med. 2022 Jul 5:1-12. doi: 10.1017/S0033291722001878.
    PubMed     Abstract available


  173. GUNASEKERA B, Wilson R, O'Neill A, Blest-Hopley G, et al
    Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
    Psychol Med. 2022 Jul 1:1-10. doi: 10.1017/S0033291722001672.
    PubMed     Abstract available


  174. LATRECHE C, Maeder J, Mancini V, Bortolin K, et al
    Altered developmental trajectories of verbal learning skills in 22q11.2DS: associations with hippocampal development and psychosis.
    Psychol Med. 2022 Jul 1:1-10. doi: 10.1017/S0033291722001842.
    PubMed     Abstract available


  175. VAN OS J, Pries LK, Ten Have M, de Graaf R, et al
    Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway.
    Psychol Med. 2022;52:1910-1922.
    PubMed     Abstract available


    June 2022
  176. TOWNSEND L, Pillinger T, Selvaggi P, Veronese M, et al
    Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of (18)FDG-PET studies in schizophrenia.
    Psychol Med. 2022 Jun 22:1-18. doi: 10.1017/S003329172200174.
    PubMed     Abstract available


  177. FUENTES-CLARAMONTE P, Salgado-Pineda P, Argila-Plaza I, Garcia-Leon MA, et al
    Neural correlates of referential/persecutory delusions in schizophrenia: examination using fMRI and a virtual reality underground travel paradigm.
    Psychol Med. 2022 Jun 22:1-8. doi: 10.1017/S0033291722001751.
    PubMed     Abstract available


  178. DE HAAN L, Linszen D, Wouters L, Zwinderman K, et al
    Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial.
    Psychol Med. 2022 Jun 8:1-8. doi: 10.1017/S003329172200099.
    PubMed     Abstract available


  179. RABALLO A, Poletti M, Preti A
    Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis.
    Psychol Med. 2022 Jun 3:1-11. doi: 10.1017/S0033291722001428.
    PubMed     Abstract available


  180. WANG HE, Cheng CM, Bai YM, Hsu JW, et al
    Familial coaggregation of major psychiatric disorders in first-degree relatives of individuals with autism spectrum disorder: a nationwide population-based study.
    Psychol Med. 2022;52:1437-1447.
    PubMed     Abstract available


    May 2022
  181. HOMAN P, Schooler NR, Brunette MF, Rotondi A, et al
    Relapse prevention through health technology program reduces hospitalization in schizophrenia.
    Psychol Med. 2022 May 30:1-7. doi: 10.1017/S0033291722000794.
    PubMed     Abstract available


  182. DESOUZA DD, Tang SX, Danilewitz M
    The burgeoning role of speech and language assessment in schizophrenia spectrum disorders.
    Psychol Med. 2022 May 18:1-2. doi: 10.1017/S0033291722001325.
    PubMed    


  183. CULBERT KM, Thakkar KN, Klump KL
    Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk.
    Psychol Med. 2022 May 18:1-9. doi: 10.1017/S0033291722001143.
    PubMed     Abstract available


  184. CZEPIELEWSKI LS, Alliende LM, Castaneda CP, Castro M, et al
    Effects of Socioeconomic Status in Cognition of People with Schizophrenia: Results From a Latin American Collaboration Network with 1175 Subjects - Corrigendum.
    Psychol Med. 2022 May 9:1. doi: 10.1017/S0033291721003949.
    PubMed    


  185. TERMORSHUIZEN F, Selten JP
    Risk of psychosis among migrants to the Netherlands by time since arrival.
    Psychol Med. 2022 May 5:1-10. doi: 10.1017/S0033291722001192.
    PubMed     Abstract available


    April 2022
  186. BADAL VD, Depp CA, Harvey PD, Ackerman RA, et al
    Confidence, accuracy judgments and feedback in schizophrenia and bipolar disorder: a time series network analysis.
    Psychol Med. 2022 Apr 28:1-10. doi: 10.1017/S0033291722000939.
    PubMed     Abstract available


  187. FREEMAN D, Rosebrock L, Waite F, Loe BS, et al
    Virtual reality (VR) therapy for patients with psychosis: satisfaction and side effects.
    Psychol Med. 2022 Apr 28:1-12. doi: 10.1017/S0033291722001167.
    PubMed     Abstract available


  188. CATALAN A, Aymerich C, Bilbao A, Pedruzo B, et al
    Psychosis and Substance Abuse increase the COVID-19 mortality risk.
    Psychol Med. 2022 Apr 12:1-23. doi: 10.1017/S0033291722000976.
    PubMed    


  189. JANG SK, Saunders G, Liu M, Jiang Y, et al
    Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder.
    Psychol Med. 2022;52:968-978.
    PubMed     Abstract available


  190. THUAIRE F, Rondepierre F, Vallet GT, Jalenques I, et al
    Executive deficits in schizophrenia: mediation by processing speed and its relationships with aging.
    Psychol Med. 2022;52:1126-1134.
    PubMed     Abstract available


  191. MORAN EK, Gold JM, Carter CS, MacDonald AW 3rd, et al
    Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks.
    Psychol Med. 2022;52:1115-1125.
    PubMed     Abstract available


  192. LEMVIGH CK, Brouwer RM, Pantelis C, Jensen MH, et al
    Heritability of specific cognitive functions and associations with schizophrenia spectrum disorders using CANTAB: a nation-wide twin study.
    Psychol Med. 2022;52:1101-1114.
    PubMed     Abstract available


  193. WORTINGER LA, Engen K, Barth C, Andreassen OA, et al
    Asphyxia at birth affects brain structure in patients on the schizophrenia-bipolar disorder spectrum and healthy participants.
    Psychol Med. 2022;52:1050-1059.
    PubMed     Abstract available


  194. NENADIC I, Meller T, Schmitt S, Stein F, et al
    Polygenic risk for schizophrenia and schizotypal traits in non-clinical subjects.
    Psychol Med. 2022;52:1069-1079.
    PubMed     Abstract available


    March 2022
  195. ROBINSON T, Ali MU, Easterbrook B, Hall W, et al
    Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis.
    Psychol Med. 2022 Mar 24:1-11. doi: 10.1017/S0033291722000502.
    PubMed     Abstract available


  196. VITA A, Barlati S, Ceraso A, Deste G, et al
    Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Psychol Med. 2022 Mar 8:1-11. doi: 10.1017/S0033291722000319.
    PubMed     Abstract available


  197. FLAATEN CB, Melle I, Gardsjord E, Bjella T, et al
    Course of intellectual functioning in schizophrenia and bipolar disorder: a 10-year follow-up study.
    Psychol Med. 2022 Mar 8:1-9. doi: 10.1017/S0033291721004645.
    PubMed     Abstract available


    February 2022
  198. DEMJAHA A, Galderisi S, Glenthoj B, Arango C, et al
    Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study.
    Psychol Med. 2022 Feb 24:1-9. doi: 10.1017/S0033291722000010.
    PubMed     Abstract available


  199. HUANG LC, Lin SH, Tseng HH, Chen KC, et al
    Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study.
    Psychol Med. 2022 Feb 24:1-8. doi: 10.1017/S003329172100533.
    PubMed     Abstract available


  200. WATSON AJ, Giordano A, Suckling J, Barnes TRE, et al
    Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers.
    Psychol Med. 2022 Feb 18:1-10. doi: 10.1017/S0033291721004815.
    PubMed     Abstract available


  201. LI M, Deng W, Li Y, Zhao L, et al
    Ameliorative patterns of grey matter in patients with first-episode and treatment-naive schizophrenia.
    Psychol Med. 2022 Feb 15:1-11. doi: 10.1017/S0033291722000058.
    PubMed     Abstract available


  202. DENG W, Addington J, Bearden CE, Cadenhead KS, et al
    Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes.
    Psychol Med. 2022 Feb 11:1-8. doi: 10.1017/S0033291722000277.
    PubMed     Abstract available


  203. HUI CLM, Wong AKH, Ho ECN, Lam BST, et al
    Effectiveness and optimal duration of early intervention treatment in adult-onset psychosis: a randomized clinical trial.
    Psychol Med. 2022 Feb 11:1-13. doi: 10.1017/S0033291721004189.
    PubMed     Abstract available


  204. DAN-GLAUSER E, Framorando D, Solida-Tozzi A, Golay P, et al
    Evolution of impulsivity levels in relation to early cannabis use in violent patients in the early phase of psychosis.
    Psychol Med. 2022 Feb 10:1-10. doi: 10.1017/S0033291721005316.
    PubMed     Abstract available


  205. PICO-PEREZ M, Vieira R, Fernandez-Rodriguez M, De Barros MAP, et al
    Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients.
    Psychol Med. 2022 Feb 7:1-11. doi: 10.1017/S0033291721005523.
    PubMed     Abstract available


  206. WILKINSON ID, Mahmood T, Yasmin SF, Tomlinson A, et al
    In memory of Professor Iain Wilkinson: cognitive and neuroimaging endophenotypes in a consanguineous schizophrenia multiplex family.
    Psychol Med. 2022 Feb 7:1-9. doi: 10.1017/S0033291721005250.
    PubMed     Abstract available


    January 2022
  207. RODRIGUEZ V, Alameda L, Quattrone D, Tripoli G, et al
    Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.
    Psychol Med. 2022 Jan 25:1-10. doi: 10.1017/S0033291721005456.
    PubMed     Abstract available


  208. LEPAGE M, Bowie CR, Montreuil T, Baer L, et al
    Manualized group cognitive behavioral therapy for social anxiety in first-episode psychosis: a randomized controlled trial.
    Psychol Med. 2022 Jan 11:1-10. doi: 10.1017/S0033291721005328.
    PubMed     Abstract available


  209. SU W, Yuan A, Tang Y, Xu L, et al
    Effects of polygenic risk of schizophrenia on interhemispheric callosal white matter integrity and frontotemporal functional connectivity in first-episode schizophrenia.
    Psychol Med. 2022 Jan 7:1-10. doi: 10.1017/S0033291721004840.
    PubMed     Abstract available


  210. SCHICK A, van Winkel R, Lin BD, Luykx JJ, et al
    Polygenic risk, familial liability and stress reactivity in psychosis: an experience sampling study.
    Psychol Med. 2022 Jan 7:1-10. doi: 10.1017/S0033291721004761.
    PubMed     Abstract available


  211. MILLGATE E, Hide O, Lawrie SM, Murray RM, et al
    Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis.
    Psychol Med. 2022;52:1-13.
    PubMed     Abstract available


  212. JONES HJ, Hammerton G, McCloud T, Hines LA, et al
    Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence.
    Psychol Med. 2022;52:132-139.
    PubMed     Abstract available


  213. RABALLO A, Poletti M
    Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
    Psychol Med. 2022;52:184-187.
    PubMed     Abstract available


    December 2021
  214. PATEL GH, Arkin SC, Ruiz-Betancourt DR, DeBaun HM, et al
    What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia.
    Psychol Med. 2021;51:2923-2932.
    PubMed     Abstract available


  215. LAVALLE L, Donde C, Gaweda L, Brunelin J, et al
    Impaired self-recognition in individuals with no full-blown psychotic symptoms represented across the continuum of psychosis: a meta-analysis.
    Psychol Med. 2021;51:2864-2874.
    PubMed     Abstract available


  216. VERDOUX H, Quiles C, Bon L, Chereau-Boudet I, et al
    Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers.
    Psychol Med. 2021;51:2789-2797.
    PubMed     Abstract available


    November 2021
  217. ROTENBERG M, Tuck A, Anderson KK, McKenzie K, et al
    Neighbourhood-level social capital, marginalisation, and the incidence of schizophrenia and schizoaffective disorder in Toronto, Canada: a retrospective population-based cohort study.
    Psychol Med. 2021 Nov 23:1-9. doi: 10.1017/S003329172100458.
    PubMed     Abstract available


  218. ERZIN G, Pries LK, Dimitrakopoulos S, Ralli I, et al
    Association between exposome score for schizophrenia and functioning in first-episode psychosis: results from the Athens first-episode psychosis research study.
    Psychol Med. 2021 Nov 18:1-10. doi: 10.1017/S0033291721004542.
    PubMed     Abstract available


  219. BRAND BA, Haveman YRA, de Beer F, de Boer JN, et al
    Antipsychotic medication for women with schizophrenia spectrum disorders.
    Psychol Med. 2021 Nov 12:1-15. doi: 10.1017/S0033291721004591.
    PubMed     Abstract available


  220. MERCHANT JT, Moran EK, Strube MJ, Barch DM, et al
    Correlates of real-world goal-directed behavior in schizophrenia.
    Psychol Med. 2021 Nov 12:1-9. doi: 10.1017/S0033291721004281.
    PubMed     Abstract available


  221. HODGINS S, Eronen M, Freese R, Hart S, et al
    Correspondence regarding De Girolamo et al., 2021 'A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project'.
    Psychol Med. 2021 Nov 2:1-2. doi: 10.1017/S0033291721004347.
    PubMed    


  222. BARRON DS
    Commentary: the ethical challenges of machine learning in psychiatry: a focus on data, diagnosis, and treatment.
    Psychol Med. 2021;51:2522-2524.
    PubMed     Abstract available


    October 2021
  223. OOMEN PP, Begemann MJH, Brand BA, de Haan L, et al
    Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis.
    Psychol Med. 2021 Oct 19:1-11. doi: 10.1017/S0033291721004153.
    PubMed     Abstract available


  224. LO LLH, Lee EHM, Hui CLM, Chong CSY, et al
    Effect of high-endurance exercise intervention on sleep-dependent procedural memory consolidation in individuals with schizophrenia: a randomized controlled trial.
    Psychol Med. 2021 Oct 7:1-13. doi: 10.1017/S0033291721003196.
    PubMed     Abstract available


    September 2021
  225. SHENG D, Pu W, Linli Z, Tian GL, et al
    Aberrant global and local dynamic properties in schizophrenia with instantaneous phase method based on Hilbert transform.
    Psychol Med. 2021 Sep 30:1-11. doi: 10.1017/S0033291721003895.
    PubMed     Abstract available


  226. EMSLEY R, du Plessis S, Phahladira L, Luckhoff HK, et al
    Antipsychotic treatment effects and structural MRI brain changes in schizophrenia.
    Psychol Med. 2021 Sep 23:1-10. doi: 10.1017/S0033291721003809.
    PubMed     Abstract available


  227. PAQUIN V, Cupo L, Malla AK, Iyer SN, et al
    Dynamic association of the first identifiable symptom with rapidity of progression to first-episode psychosis.
    Psychol Med. 2021 Sep 20:1-9. doi: 10.1017/S0033291721003755.
    PubMed     Abstract available


  228. DE GIROLAMO G, Iozzino L, Ferrari C, Gosek P, et al
    A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project.
    Psychol Med. 2021 Sep 13:1-11. doi: 10.1017/S0033291721003433.
    PubMed     Abstract available


  229. GARRIDO-TORRES N, Rocha-Gonzalez I, Alameda L, Rodriguez-Gangoso A, et al
    Metabolic syndrome in antipsychotic-naive patients with first-episode psychosis: a systematic review and meta-analysis.
    Psychol Med. 2021 Sep 8:1-14. doi: 10.1017/S0033291721002853.
    PubMed     Abstract available


  230. LI X, Deng W, Xue R, Wang Q, et al
    Auditory event-related potentials, neurocognition, and global functioning in drug naive first-episode schizophrenia and bipolar disorder.
    Psychol Med. 2021 Sep 3:1-10. doi: 10.1017/S0033291721002130.
    PubMed     Abstract available


  231. FRAWLEY E, Cowman M, Lepage M, Donohoe G, et al
    Social and occupational recovery in early psychosis: a systematic review and meta-analysis of psychosocial interventions.
    Psychol Med. 2021 Sep 3:1-12. doi: 10.1017/S003329172100341.
    PubMed     Abstract available


  232. HJERN A, Palacios J, Vinnerljung B
    Early childhood adversity and non-affective psychosis: a study of refugees and international adoptees in Sweden.
    Psychol Med. 2021 Sep 2:1-10. doi: 10.1017/S003329172100355.
    PubMed     Abstract available


  233. KIM M, Kim T, Hwang WJ, Lho SK, et al
    Forecasting prognostic trajectories with mismatch negativity in early psychosis.
    Psychol Med. 2021 Sep 2:1-11. doi: 10.1017/S0033291721003068.
    PubMed     Abstract available


  234. SAMI M, Quattrone D, Ferraro L, Tripoli G, et al
    Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls.
    Psychol Med. 2021;51:2074-2082.
    PubMed     Abstract available


  235. CSUKLY G, Szabo A, Polgar P, Farkas K, et al
    Fronto-thalamic structural and effective connectivity and delusions in schizophrenia: a combined DTI/DCM study.
    Psychol Med. 2021;51:2083-2093.
    PubMed     Abstract available


  236. BALLESTEROS A, Sanchez Torres AM, Lopez-Ilundain J, Mezquida G, et al
    The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Psychol Med. 2021;51:2044-2053.
    PubMed     Abstract available


  237. ZHANG T, Xu L, Chen Y, Wei Y, et al
    Conversion to psychosis in adolescents and adults: similar proportions, different predictors.
    Psychol Med. 2021;51:2003-2011.
    PubMed     Abstract available


    August 2021
  238. MARTLAND R, Teasdale S, Murray RM, Gardner-Sood P, et al
    Dietary intake, physical activity and sedentary behaviour patterns in a sample with established psychosis and associations with mental health symptomatology.
    Psychol Med. 2021 Aug 23:1-11. doi: 10.1017/S0033291721003147.
    PubMed     Abstract available


  239. ALLARDYCE J, Hollander AC, Rahman S, Dalman C, et al
    Association of trauma, post-traumatic stress disorder and non-affective psychosis across the life course: a nationwide prospective cohort study.
    Psychol Med. 2021 Aug 20:1-9. doi: 10.1017/S0033291721003287.
    PubMed     Abstract available


  240. COORS A, Imtiaz MA, Boenniger MM, Aziz NA, et al
    Polygenic risk scores for schizophrenia are associated with oculomotor endophenotypes.
    Psychol Med. 2021 Aug 20:1-9. doi: 10.1017/S0033291721003251.
    PubMed     Abstract available


  241. MOFFA G, Kuipers J, Carra G, Crocamo C, et al
    Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs.
    Psychol Med. 2021 Aug 5:1-8. doi: 10.1017/S0033291721002920.
    PubMed     Abstract available


  242. LEMVIGH C, Brouwer R, Hilker R, Anhoj S, et al
    The relative and interactive impact of multiple risk factors in schizophrenia spectrum disorders: a combined register-based and clinical twin study.
    Psychol Med. 2021 Aug 5:1-11. doi: 10.1017/S0033291721002749.
    PubMed     Abstract available


  243. DE BOER JN, Voppel AE, Brederoo SG, Schnack HG, et al
    Acoustic speech markers for schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool.
    Psychol Med. 2021 Aug 4:1-11. doi: 10.1017/S0033291721002804.
    PubMed     Abstract available


  244. ZHAO W, Zhang Q, Chen X, Li Y, et al
    The VNTR of the AS3MT gene is associated with brain activations during a memory span task and their training-induced plasticity.
    Psychol Med. 2021;51:1927-1932.
    PubMed     Abstract available


    July 2021
  245. WIESSNER I, Falchi M, Palhano-Fontes F, Feilding A, et al
    LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Psychol Med. 2021 Jul 13:1-15. doi: 10.1017/S0033291721002531.
    PubMed     Abstract available


  246. JOHNSON EC, Kapoor M, Hatoum AS, Zhou H, et al
    Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder.
    Psychol Med. 2021 Jul 7:1-9. doi: 10.1017/S003329172100266.
    PubMed     Abstract available


  247. FAGERLUND B, Pantelis C, Jepsen JRM, Raghava JM, et al
    Differential effects of age at illness onset on verbal memory functions in antipsychotic-naive schizophrenia patients aged 12-43 years.
    Psychol Med. 2021;51:1570-1580.
    PubMed     Abstract available


  248. NEUMANN SR, Glue P, Linscott RJ
    Aberrant salience and reward processing: a comparison of measures in schizophrenia and anxiety.
    Psychol Med. 2021;51:1507-1515.
    PubMed     Abstract available


  249. JONGSMA HE, Gayer-Anderson C, Tarricone I, Velthorst E, et al
    Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.
    Psychol Med. 2021;51:1536-1548.
    PubMed     Abstract available


  250. LIEBERS DT, Pirooznia M, Ganna A, Goes FS, et al
    Discriminating bipolar depression from major depressive disorder with polygenic risk scores.
    Psychol Med. 2021;51:1451-1458.
    PubMed     Abstract available


  251. CHRETIEN B, Lelong-Boulouard V, Chantepie S, Sassier M, et al
    Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase((R)).
    Psychol Med. 2021;51:1459-1466.
    PubMed     Abstract available


  252. RAUSCHENBERG C, Reininghaus U, Ten Have M, de Graaf R, et al
    The jumping to conclusions reasoning bias as a cognitive factor contributing to psychosis progression and persistence: findings from NEMESIS-2.
    Psychol Med. 2021;51:1696-1703.
    PubMed     Abstract available


  253. KOWALCZYK OS, Pauls AM, Fuste M, Williams SCR, et al
    Neurocognitive correlates of working memory and emotional processing in postpartum psychosis: an fMRI study.
    Psychol Med. 2021;51:1724-1732.
    PubMed     Abstract available


  254. CUESTA MJ, Lecumberri P, Moreno-Izco L, Lopez-Ilundain JM, et al
    Motor abnormalities and basal ganglia in first-episode psychosis (FEP).
    Psychol Med. 2021;51:1625-1636.
    PubMed     Abstract available


    June 2021
  255. CZEPIELEWSKI LS, Alliende LM, Castaneda CP, Castro M, et al
    Effects of socioeconomic status in cognition of people with schizophrenia: results from a Latin American collaboration network with 1175 subjects.
    Psychol Med. 2021 Jun 23:1-12. doi: 10.1017/S0033291721002403.
    PubMed     Abstract available


  256. SCHOFIELD P, Das-Munshi J, Webb RT, Horsdal HT, et al
    Lack of fit with the neighbourhood social environment as a risk factor for psychosis - a national cohort study.
    Psychol Med. 2021 Jun 18:1-9. doi: 10.1017/S0033291721002233.
    PubMed     Abstract available


  257. STRAUSS GP, Bartolomeo LA, Luther L
    Reduced willingness to expend effort for rewards is associated with risk for conversion and negative symptom severity in youth at clinical high-risk for psychosis.
    Psychol Med. 2021 Jun 14:1-8. doi: 10.1017/S003329172100204.
    PubMed     Abstract available


  258. DONG D, Yao D, Wang Y, Hong SJ, et al
    Compressed sensorimotor-to-transmodal hierarchical organization in schizophrenia.
    Psychol Med. 2021 Jun 8:1-14. doi: 10.1017/S0033291721002129.
    PubMed     Abstract available


  259. QUATTRONE D, Ferraro L, Tripoli G, La Cascia C, et al
    Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
    Psychol Med. 2021;51:1329-1337.
    PubMed     Abstract available


  260. KING M, Jones R, Petersen I, Hamilton F, et al
    Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses.
    Psychol Med. 2021;51:1373-1381.
    PubMed     Abstract available


  261. OSBORNE KJ, Damme KSF, Gupta T, Dean DJ, et al
    Timing dysfunction and cerebellar resting state functional connectivity abnormalities in youth at clinical high-risk for psychosis.
    Psychol Med. 2021;51:1289-1298.
    PubMed     Abstract available


    May 2021
  262. STAFFORD J, Dykxhoorn J, Sommerlad A, Dalman C, et al
    Association between risk of dementia and very late-onset schizophrenia-like psychosis: a Swedish population-based cohort study.
    Psychol Med. 2021 May 25:1-9. doi: 10.1017/S0033291721002099.
    PubMed     Abstract available


  263. O'DONOGHUE B, Lyne J, Roche E, Mifsud N, et al
    Risk of first-episode psychosis in migrants to the Republic of Ireland.
    Psychol Med. 2021 May 25:1-8. doi: 10.1017/S003329172100177.
    PubMed     Abstract available


  264. LINDGREN M, Kuvaja H, Jokela M, Therman S, et al
    Predictive validity of psychosis risk models when applied to adolescent psychiatric patients.
    Psychol Med. 2021 May 24:1-12. doi: 10.1017/S0033291721001938.
    PubMed     Abstract available


  265. AYESA-ARRIOLA R, Miguel-Corredera M, de la Foz VO, Neergaard KD, et al
    Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort.
    Psychol Med. 2021 May 6:1-12. doi: 10.1017/S0033291721001112.
    PubMed     Abstract available


  266. WEARNE TA, McDonald S
    Social cognition v. emotional intelligence in first-episode psychosis: are they the same?
    Psychol Med. 2021;51:1229-1230.
    PubMed    


    April 2021
  267. ZHANG R, Kuja-Halkola R, Birgegard A, Larsson H, et al
    Association of family history of schizophrenia and clinical outcomes in individuals with eating disorders.
    Psychol Med. 2021 Apr 30:1-8. doi: 10.1017/S0033291721001574.
    PubMed     Abstract available


  268. MCHUGO M, Avery S, Armstrong K, Rogers BP, et al
    Anterior hippocampal dysfunction in early psychosis: a 2-year follow-up study.
    Psychol Med. 2021 Apr 20:1-10. doi: 10.1017/S0033291721001318.
    PubMed     Abstract available


  269. SEDGWICK O, Hardy A, Newbery K, Cella M, et al
    A systematic review of adherence to group interventions in psychosis: do people attend?
    Psychol Med. 2021 Apr 16:1-9. doi: 10.1017/S0033291721000404.
    PubMed     Abstract available


  270. JOO SW, Kim H, Jo YT, Choi YJ, et al
    Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
    Psychol Med. 2021 Apr 15:1-8. doi: 10.1017/S0033291721001379.
    PubMed     Abstract available


  271. SWERDLOW NR, Bhakta SG, Talledo J, Benster L, et al
    Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course.
    Psychol Med. 2021 Apr 14:1-9. doi: 10.1017/S0033291721001239.
    PubMed     Abstract available


  272. VAN LEEUWEN JMC, Vinkers CH, Vink M, Kahn RS, et al
    Disrupted upregulation of salience network connectivity during acute stress in siblings of schizophrenia patients.
    Psychol Med. 2021;51:1038-1048.
    PubMed     Abstract available


  273. GUO JY, Lesh TA, Niendam TA, Ragland JD, et al
    Brain free water alterations in first-episode psychosis: a longitudinal analysis of diagnosis, course of illness, and medication effects.
    Psychol Med. 2021;51:1001-1010.
    PubMed     Abstract available


  274. POKORNY VJ, Lano TJ, Schallmo MP, Olman CA, et al
    Reduced influence of perceptual context in schizophrenia: behavioral and neurophysiological evidence.
    Psychol Med. 2021;51:786-794.
    PubMed     Abstract available


  275. PEREZ J, Jones PB
    Breaking the web: life beyond the at-risk mental state for psychosis.
    Psychol Med. 2021;51:934-939.
    PubMed     Abstract available


    March 2021
  276. O'NEILL A, Wilson R, Blest-Hopley G, Annibale L, et al
    Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    Psychol Med. 2021;51:596-606.
    PubMed     Abstract available


  277. HUANG MH, Cheng CM, Tsai SJ, Bai YM, et al
    Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: a nationwide study.
    Psychol Med. 2021;51:680-687.
    PubMed     Abstract available


  278. NKIRE N, Scully PJ, Browne DJ, Baldwin PA, et al
    Systematic epidemiological and clinical comparisons across all 12 DSM-IV psychotic diagnoses in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).
    Psychol Med. 2021;51:607-616.
    PubMed     Abstract available


  279. ZHANG T, Xu L, Li H, Woodberry KA, et al
    Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program.
    Psychol Med. 2021;51:653-660.
    PubMed     Abstract available


  280. HJORTHOJ C, Larsen MO, Starzer MSK, Nordentoft M, et al
    Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016.
    Psychol Med. 2021;51:617-622.
    PubMed     Abstract available


    February 2021
  281. SIAFIS S, Davis JM, Leucht S
    Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature.
    Psychol Med. 2021;51:522-524.
    PubMed    


  282. MONCRIEFF J, Cohen D
    Antipsychotics as particular types of sedatives.
    Psychol Med. 2021;51:521.
    PubMed    


  283. HERBENER ES, Harrow M
    Course and symptom and functional correlates of passivity symptoms in schizophrenia: an 18-year multi-follow-up longitudinal study.
    Psychol Med. 2021;51:503-510.
    PubMed     Abstract available


  284. LIU Y, Mendonca M, Johnson S, O'Reilly H, et al
    Testing the neurodevelopmental, trauma and developmental risk factor models of psychosis using a naturalistic experiment.
    Psychol Med. 2021;51:460-469.
    PubMed     Abstract available


  285. HJORTHOJ C, Uddin MJ, Wimberley T, Dalsgaard S, et al
    No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder.
    Psychol Med. 2021;51:479-484.
    PubMed     Abstract available


    January 2021
  286. VIEIRA S, Gong Q, Scarpazza C, Lui S, et al
    Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis.
    Psychol Med. 2021;51:340-350.
    PubMed     Abstract available


  287. DAVIES SJC, Iwajomo T, de Oliveira C, Versloot J, et al
    The impact of psychiatric and medical comorbidity on the risk of mortality: a population-based analysis.
    Psychol Med. 2021;51:320-328.
    PubMed     Abstract available


  288. ODUOLA S, Das-Munshi J, Bourque F, Gayer-Anderson C, et al
    Change in incidence rates for psychosis in different ethnic groups in south London: findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study.
    Psychol Med. 2021;51:300-309.
    PubMed     Abstract available


  289. AYESA-ARRIOLA R, Ortiz-Garcia de la Foz V, Martinez-Garcia O, Setien-Suero E, et al
    Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort.
    Psychol Med. 2021;51:264-277.
    PubMed     Abstract available


  290. MARTIN-SUBERO M, Fuentes-Claramonte P, Salgado-Pineda P, Salavert J, et al
    Autobiographical memory and default mode network function in schizophrenia: an fMRI study.
    Psychol Med. 2021;51:121-128.
    PubMed     Abstract available


  291. BRUCATO G, First MB, Dishy GA, Samuel SS, et al
    Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients.
    Psychol Med. 2021;51:112-120.
    PubMed     Abstract available


  292. SMART SE, Kepinska AP, Murray RM, MacCabe JH, et al
    Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies.
    Psychol Med. 2021;51:44-53.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.